|
1
|
Mayekar MK and Bivona TG: Current
landscape of targeted therapy in lung cancer. Clin Pharmacol Ther.
102:757–764. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Somasundaram A and Burns TF: The next
generation of immunotherapy: Keeping lung cancer in check. J
Hematol Oncol. 10:872017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khanna P, Blais N, Gaudreau PO and
Corrales-Rodriguez L: Immunotherapy comes of age in lung cancer.
Clin Lung Cancer. 18:13–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wehler T, Wehler B and Stehle I:
Immunotherapy in lung cancer: Checkpoint inhibitors. Deutsche
medizinische Wochenschrift. 140:1835–1838. 2015.(In German).
PubMed/NCBI
|
|
5
|
Quaratino S, Forssmann U and Marschner JP:
New approaches in immunotherapy for the treatment of lung cancer.
Curr Top Microbiol Immunol. 405:1–31. 2017.PubMed/NCBI
|
|
6
|
Ettinger DS: Immunotherapy for lung
cancer: Many questions yet to be answered. J Natl Compr Canc Netw.
14:935–938. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goubet AG, Livartowski A and Romano E:
Immunotherapy in lung cancer: New concepts. Rev Mal Respir.
35:642–651. 2018.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sánchez de Cos Escuín J: New immunotherapy
and lung cancer. Arch Bronconeumol. 53:682–687. 2017.(In English,
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seehus CR and Kaye J: The role of TOX in
the development of innate lymphoid cells. Mediators Inflamm.
2015:2438682015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu X and Li Z: TOX gene: A novel target
for human cancer gene therapy. Am J Cancer Res. 5:3516–3524.
2015.PubMed/NCBI
|
|
11
|
Han CC, Yue LL, Yang Y, Jian BY, Ma LW and
Liu JC: TOX3 protein expression is correlated with pathological
characteristics in breast cancer. Oncol Lett. 11:1762–1768. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schrader AM, Jansen PM and Willemze R: TOX
expression in cutaneous T-cell lymphomas: An adjunctive diagnostic
marker that is not tumour specific and not restricted to the CD4(+)
CD8(−) phenotype. Br J Dermatol. 175:382–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tessema M, Yingling CM, Grimes MJ, Thomas
CL, Liu Y, Leng S, Joste N and Belinsky SA: Differential epigenetic
regulation of TOX subfamily high mobility group box genes in lung
and breast cancers. PLoS One. 7:e348502012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, Zhu H, Wu X, Wang M, Gu D, Gong
W, Xu Z, Tan Y, Gong Y, Zhou J, et al: A genetic polymorphism in
TOX3 is associated with survival of gastric cancer in a Chinese
population. PLoS One. 8:e721862013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu W, Wagner EK, Hao Y, Rao X, Dai H, Han
J, Chen J, Storniolo AMV, Liu Y and He C: Tissue-specific
co-expression of long non-coding and coding RNAs associated with
breast cancer. Sci Rep. 6:327312016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin HY, Zeng, Liang YK, Wei XL and Chen
CF: GATA3 and TRPS1 are distinct biomarkers and prognostic factors
in breast cancer: Database mining for GATA family members in
malignancies. Oncotarget. 8:34750–34761. 2017.PubMed/NCBI
|
|
19
|
Györffy B, Lanczky A, Eklund AC, Denkert
C, Budczies J, Li Q and Szallasi Z: An online survival analysis
tool to rapidly assess the effect of 22,277 genes on breast cancer
prognosis using microarray data of 1,809 patients. Breast Cancer
Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stearman RS, Dwyer-Nield L, Zerbe L,
Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT,
Franklin WA, et al: Analysis of orthologous gene expression between
human pulmonary adenocarcinoma and a carcinogen-induced murine
model. Am J Pathol. 167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Landi MT, Dracheva T, Rotunno M, Figueroa
JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et
al: Gene expression signature of cigarette smoking and its role in
lung adenocarcinoma development and survival. PLoS One.
3:e16512008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hou J, Aerts J, den Hamer B, van Ijcken W,
den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens
JA, Hoogsteden HC, et al: Gene expression-based classification of
non-small cell lung carcinomas and survival prediction. PLoS One.
5:e103122010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Du L, Herbst RS and Morgensztern D:
Immunotherapy in lung cancer. Hematol Oncol Clin North Am.
31:131–141. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valecha GK, Vennepureddy A, Ibrahim U,
Safa F, Samra B and Atallah JP: Anti-PD-1/PD-L1 antibodies in
non-small cell lung cancer: The era of immunotherapy. Expert Rev
Anticancer Ther. 17:47–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seksenyan A, Kadavallore A, Walts AE, de
la Torre B, Berel D, Strom SP, Aliahmad P, Funari VA and Kaye J:
TOX3 is expressed in mammary ER(+) epithelial cells and regulates
ER target genes in luminal breast cancer. BMC Cancer. 15:222015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li L, Guo G, Wang F, Lv P, Zhu M, Gu Y,
Han M and Pei X: TOX high mobility group box family member 3
rs3803662 and breast cancer risk: A meta-analysis. J Cancer Res
Ther. 14 (Suppl):S208–S212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Cai P, Liang T, Wang L and Hu L:
TIM-3 is a potential prognostic marker for patients with solid
tumors: A systematic review and meta-analysis. Oncotarget.
8:31705–31713. 2017.PubMed/NCBI
|
|
30
|
Riaz M, Berns EM, Sieuwerts AM,
Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look
MP, Klijn JG, Sleijfer S, et al: Correlation of breast cancer
susceptibility loci with patient characteristics, metastasis-free
survival, and mRNA expression of the nearest genes. Breast Cancer
Res Treat. 133:843–851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nishioka Y: Cancer immunotherapy as a
promising fourth standard therapy for lung cancer: Beyond 20 years
for the development of immunotherapy. Respir Investig. 54:2972016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dal Bello MG, Alama A, Coco S, Vanni I and
Grossi F: Understanding the checkpoint blockade in lung cancer
immunotherapy. Drug Discov Today. 22:1266–1273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chae YK, Arya A, Iams W, Cruz M, Mohindra
N, Villaflor V and Giles FJ: Immune checkpoint pathways in
non-small cell lung cancer. Ann Transl Med. 6:882018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berghmans T, Grigoriu B, Sculier JP and
Meert AP: Immune checkpoint inhibitors (antibodies to PD1 and
PD-L1), a new therapeutic weapon against non-small cell bronchial
carcinoma. Rev Mal Respir. 35:197–205. 2018.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Berghmans T and Meert AP: Immunotherapy
and non-small cell lung cancer: A (r)evolution. Rev Med Brux.
38:175–177. 2017.(In French). PubMed/NCBI
|
|
36
|
Anderson AC: Tim-3: An emerging target in
the cancer immunotherapy landscape. Cancer Immunol Res. 2:393–398.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu F, Zeng G, Zhou S, He X, Sun N, Zhu X
and Hu A: Blocking Tim-3 or/and PD-1 reverses dysfunction of
tumor-infiltrating lymphocytes in HBV-related hepatocellular
carcinoma. Bull Cancer. 105:493–501. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao J, Qiu X, Li X, Fan H, Zhang F, Lv T
and Song Y: Expression profiles and clinical value of plasma
exosomal Tim-3 and Galectin-9 in non-small cell lung cancer.
Biochem Biophys Res Commun. 498:409–415. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Das M, Zhu C and Kuchroo VK: Tim-3 and its
role in regulating anti-tumor immunity. Immunol Rev. 276:97–111.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yu M, Lu B, Liu Y, Me Y, Wang L and Zhang
P: Tim-3 is upregulated in human colorectal carcinoma and
associated with tumor progression. Mol Med Rep. 15:689–695. 2017.
View Article : Google Scholar : PubMed/NCBI
|
